Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.09) by 55.56 percent. This is a 109.76 percent decrease over earnings of $0.41 per share from the same period last year. The company reported quarterly sales of $8.75 million which beat the analyst consensus estimate of $8.18 million by 6.97 percent. This is a 65.52 percent decrease over sales of $25.38 million the same period last year.